...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of nanoscience and nanotechnology >Study on the Efficacy of Nanoantibiotics in Rats with Sepsis Based on MicroRNA-195 and TGF-β1/Smads Signaling Pathway
【24h】

Study on the Efficacy of Nanoantibiotics in Rats with Sepsis Based on MicroRNA-195 and TGF-β1/Smads Signaling Pathway

机译：基于MicroRNA-195和TGF-β1/ Smads信号通路对败血症大鼠纳米生物学患者大鼠疗效的研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In order to explore the efficacy of nanoantibiotics in rats with sepsis based on MicroRNA-195 and TGF-β1/Smads signaling pathway, a total of 160 Wistar rats with sepsis were selected and randomly divided into 4 groups of general antibiotics (GA) treatment group and nanoantibioticstreatment (NT) group, MicroRNA-195 treatment (MT) group and TGF-β1/Smads (TS) treatment group with 40 sepsis rates in each group. After each group was treated for 24 hours, the supernatant was centrifuged, the enzyme-labeled reagent was added to sample wall, the absorbance valueof each well in sequence was measured, and the linear regression equation of the standard curve was calculated based on the concentration and absorbance value of the standard. Before and after the experiment, the changes in body weight, mental state, activity, respiration, and abdominal cavityof species rats in each group were observed and measured; the expression of Interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-10 (IL-10), TGF-β1, Smad2, Smad3, Smad7 were recorded and analyzed. The results showedthat the expression levels of IL-1, TNF-α, TGF-β1, Smad2, Smad3 and Smad7 in sepsis rats in GA group were higher than those in the NT group (P α, IL-6, TGF-β1, Smad2, Smad3, and Smad7 were significantly reduced (P β1/Smads may promote cardiac remodeling in sepsis rats by up-regulatingthe nanoantibiotics signaling transduction pathway, thereby having objective curative effect on sepsis rats. The study results of this paper provide a reference for further research on the efficacy of nanoantibiotics in sepsis rats based on MicroRNA-195 and TGF-β1/Smads signalingpathway.
机译：为了探索基于MicroRNA-195和TGF-β1/Smads信号通路的纳米抗生素对脓毒症大鼠的疗效，选择160只脓毒症Wistar大鼠，随机分为4组：普通抗生素（GA）治疗组和纳米抗生素治疗（NT）组，MicroRNA-195治疗（MT）组和TGF-β1/Smads（TS）治疗组各有40例败血症发生率。各组处理24小时后，离心上清液，将酶标记试剂加入样品壁，依次测量每个孔的吸光度值，并根据标准品的浓度和吸光度值计算标准曲线的线性回归方程。观察和测量实验前后各组大鼠的体重、精神状态、活动、呼吸和腹腔空洞的变化；记录并分析白细胞介素-1（IL-1）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、白细胞介素-10（IL-10）、TGF-β1、Smad2、Smad3、Smad7的表达。结果表明，IL-1、TNF-α、TGF-β1、Smad2、IL-1、TNF-α、TGF-β1、Smad2、TGF-β1、TGF-β1、Smad2、TGF-β1、Smad2、TGF-β1、Smad2、Sm，GA组脓毒症大鼠的Smad3和Smad7均高于NT组（Pα、IL-6、TGF-β1、Smad2、Smad3和Smad7显著降低）（Pβ1/Smads可能通过上调纳米抗生素信号转导途径促进脓毒症大鼠心脏重塑，从而对脓毒症大鼠具有客观疗效。本文的研究结果为进一步研究基于MicroRNA-195和TGF-β1/Smads信号通路的纳米抗生素对脓毒症大鼠的疗效提供了参考。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号